Page 19 - Agenus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Agenus (NASDAQ:AGEN – Get Rating) and Kymera Therapeutics (NASDAQ:KYMR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Analyst Recommendations This is a summary of current ratings and […]

Equities research analysts predict that Agenus Inc. (NASDAQ:AGEN – Get Rating) will post sales of $17.35 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Agenus’ earnings. The highest sales estimate is $19.70 million and the lowest is $15.00 million. Agenus reported sales of $11.72 million in the same […]

Agenus Inc. (NASDAQ:AGEN – Get Rating) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 20,010,000 shares, a drop of 23.0% from the March 15th total of 26,000,000 shares. Based on an average daily trading volume, of 4,240,000 shares, the […]

Genus plc (OTCMKTS:GENSF – Get Rating) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 200 shares, a decrease of 66.7% from the March 15th total of 600 shares. Based on an average daily volume of 600 shares, the short-interest […]

Genus (LON:GNS – Get Rating)‘s stock had its “hold” rating restated by Peel Hunt in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a GBX 4,500 ($58.64) target price on the stock. Peel Hunt’s target price suggests a potential upside of 70.71% from the stock’s current price. LON GNS opened […]